- 1.
Ystrøm T. Én sykdom – to helt forskjellige skjebner. NRK 11.11.2023. https://www.nrk.no/rogaland/xl/bade-tommy-herredsvela-og-line-flesjaa-har-ms-_-men-line-har-tatt-stamcellebehandling-1.16610171 Lest 23.11.2023.
- 2.
Helsedirektoratet. Nasjonal faglig retningslinje. Multippel sklerose. https://www.helsedirektoratet.no/retningslinjer/multippel-sklerose Lest 15.10.2023
- 3.
Holmøy T, Nygaard GO, Myhr KM et al. Behandling som begrenser multippel sklerose. Tidsskr Nor Legeforen 2021; 141. doi: 10.4045/tidsskr.21.0155. [PubMed][CrossRef]
- 4.
Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med 2020; 133: 1380–1390.e2. [PubMed][CrossRef]
- 5.
Sharrack B, Saccardi R, Alexander T et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant 2020; 55: 283–306. [PubMed][CrossRef]
- 6.
Nabizadeh F, Pirahesh K, Rafiei N et al. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Neurol Ther 2022; 11: 1553–69. [PubMed][CrossRef]
- 7.
Muraro PA. Resetting tolerance in autoimmune disease. Science 2023; 380: 470–1. [PubMed][CrossRef]
- 8.
Nasjonalt kunnskapssenter for helsetjenesten. Autolog hematopoietisk stamcelletransplantasjon ved multippel sklerose. https://nyemetoder.no/Documents/Rapporter/Rapport_2015_23_MS_Stamceller.pdf Lest 15.10.2023.
- 9.
Fassas A, Anagnostopoulos A, Kazis A et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997; 20: 631–8. [PubMed][CrossRef]
- 10.
Mancardi GL, Sormani MP, Gualandi F et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015; 84: 981–8. [PubMed][CrossRef]
- 11.
Burt RK, Balabanov R, Burman J et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA 2019; 321: 165–74. [PubMed][CrossRef]
- 12.
Kalincik T, Sharmin S, Roos I et al. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurol 2023; 80: 702–13. [PubMed][CrossRef]
- 13.
Kvistad SAS, Lehmann AK, Trovik LH et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Mult Scler 2020; 26: 1889–97. [PubMed][CrossRef]
- 14.
Luna G, Alping P, Burman J et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol 2020; 77: 184–91. [PubMed][CrossRef]
- 15.
Das J, Snowden JA, Burman J et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis. Mult Scler 2021; 27: 1198–204. [PubMed][CrossRef]
()
Prisverdig initiativ, men misvisende, for lite og for sent
13.02.2024Forfatterne skriver at høyeffektiv immunmodulerende behandling med bremsemedisiner er god behandling for de fleste, men at noen likevel opplever attakk og sykdomsforverring (1). Jeg mener at dette er misvisende, siden over 50 prosent fortsatt har…